Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
Oil Prices Rise as US-Iran Talks Stall, Inflation Risks Grow 
Wall Street Slips as Oil Prices Surge 5% on Iran-Hormuz Uncertainty 
Gold Prices Rise as Fed Rate Hike Bets Ease 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
US Judge Dismisses Gautam Adani Criminal Charges 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Asian Currencies Steady as Markets Await U.S. Inflation Data 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
South Korean pharmaceutical and biotech companies are collaborating to develop new drugs using artificial intelligence (AI).
AI can predict whether a chemical compound is suitable for human use, thereby speeding up the identification of potential substances and enabling the selection of appropriate clinical patients.
There are over 100 cases where candidate substances for new drugs are under development using AI, with over 50 percent carried out through collaborations between domestic and foreign companies, according to the Korea Pharmaceutical and Bio-pharma Manufacturers Association.
HK inno.N Corp. and AinB recently signed an MOU to identify a new antibody candidate substance for cell and gene therapies and establish an antigen design platform for vaccine development.
Last year, Pharos iBio inked a deal with Yuhan Corp. to promote the joint study and technology transfer of the AI-based KRAS inhibitor.
This company is now carrying out a phase 1 clinical trial in Korea and Australia after developing PHI-101, a candidate substance for the treatment of leukemia, using its AI platform, Chemiverse.
Moreover, Oncocross, which has AI technology to identify the optimal disease for drugs, signed a joint study and development contract with Boryung Corp. in February to expand the indications of hypertension treatment.
